Logo image of QNRX

QUOIN PHARMACEUTICALS LT-ADR (QNRX) Stock Fundamental Analysis

NASDAQ:QNRX - Nasdaq - US74907L4095 - ADR - Currency: USD

8.38  -0.09 (-1.06%)

After market: 8.75 +0.37 (+4.42%)

Fundamental Rating

1

Taking everything into account, QNRX scores 1 out of 10 in our fundamental rating. QNRX was compared to 559 industry peers in the Biotechnology industry. QNRX has a bad profitability rating. Also its financial health evaluation is rather negative. QNRX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

QNRX had negative earnings in the past year.
QNRX had a negative operating cash flow in the past year.
In the past 5 years QNRX always reported negative net income.
In the past 5 years QNRX always reported negative operating cash flow.
QNRX Yearly Net Income VS EBIT VS OCF VS FCFQNRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

QNRX's Return On Assets of -80.64% is on the low side compared to the rest of the industry. QNRX is outperformed by 70.48% of its industry peers.
QNRX's Return On Equity of -176.30% is on the low side compared to the rest of the industry. QNRX is outperformed by 64.94% of its industry peers.
Industry RankSector Rank
ROA -80.64%
ROE -176.3%
ROIC N/A
ROA(3y)-64.6%
ROA(5y)-101.86%
ROE(3y)-126.09%
ROE(5y)-748.48%
ROIC(3y)N/A
ROIC(5y)N/A
QNRX Yearly ROA, ROE, ROICQNRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

1.3 Margins

QNRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
QNRX Yearly Profit, Operating, Gross MarginsQNRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

QNRX has more shares outstanding than it did 1 year ago.
QNRX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for QNRX has been reduced compared to a year ago.
QNRX Yearly Shares OutstandingQNRX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
QNRX Yearly Total Debt VS Total AssetsQNRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -8.05, we must say that QNRX is in the distress zone and has some risk of bankruptcy.
QNRX has a Altman-Z score of -8.05. This is in the lower half of the industry: QNRX underperforms 70.13% of its industry peers.
A Debt/Equity ratio of 0.47 indicates that QNRX is not too dependend on debt financing.
QNRX has a worse Debt to Equity ratio (0.47) than 73.52% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF N/A
Altman-Z -8.05
ROIC/WACCN/A
WACCN/A
QNRX Yearly LT Debt VS Equity VS FCFQNRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 5M -5M

2.3 Liquidity

A Current Ratio of 2.57 indicates that QNRX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.57, QNRX is doing worse than 69.23% of the companies in the same industry.
A Quick Ratio of 2.57 indicates that QNRX has no problem at all paying its short term obligations.
QNRX's Quick ratio of 2.57 is on the low side compared to the rest of the industry. QNRX is outperformed by 67.08% of its industry peers.
Industry RankSector Rank
Current Ratio 2.57
Quick Ratio 2.57
QNRX Yearly Current Assets VS Current LiabilitesQNRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 5M 10M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 80.80% over the past year.
EPS 1Y (TTM)80.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.27%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

QNRX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.28% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y62.04%
EPS Next 2Y35.06%
EPS Next 3Y29.28%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
QNRX Yearly Revenue VS EstimatesQNRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 20M 40M 60M 80M 100M
QNRX Yearly EPS VS EstimatesQNRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2021 2022 2023 2024 2025 2026 2027 0 -50K -100K -150K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for QNRX. In the last year negative earnings were reported.
Also next year QNRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
QNRX Price Earnings VS Forward Price EarningsQNRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
QNRX Per share dataQNRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 -20 -30 -40

4.3 Compensation for Growth

QNRX's earnings are expected to grow with 29.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.06%
EPS Next 3Y29.28%

More info and screens

0

5. Dividend

5.1 Amount

QNRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

QUOIN PHARMACEUTICALS LT-ADR

NASDAQ:QNRX (6/13/2025, 8:00:01 PM)

After market: 8.75 +0.37 (+4.42%)

8.38

-0.09 (-1.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-06 2025-08-06
Inst Owners1.95%
Inst Owner Change-72.85%
Ins Owners7.08%
Ins Owner Change91.52%
Market Cap4.93M
Analysts82.5
Price Target51 (508.59%)
Short Float %41.1%
Short Ratio0.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)10.18%
Min EPS beat(2)-5.04%
Max EPS beat(2)25.4%
EPS beat(4)3
Avg EPS beat(4)16.07%
Min EPS beat(4)-5.04%
Max EPS beat(4)37.32%
EPS beat(8)6
Avg EPS beat(8)11.09%
EPS beat(12)8
Avg EPS beat(12)11.2%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-16.94%
PT rev (3m)1011.11%
EPS NQ rev (1m)-17.62%
EPS NQ rev (3m)N/A
EPS NY rev (1m)15.56%
EPS NY rev (3m)-2073.86%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.83
P/tB 0.9
EV/EBITDA N/A
EPS(TTM)-48.85
EYN/A
EPS(NY)-14.28
Fwd EYN/A
FCF(TTM)-15.33
FCFYN/A
OCF(TTM)-15.33
OCFYN/A
SpS0
BVpS10.07
TBVpS9.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -80.64%
ROE -176.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-64.6%
ROA(5y)-101.86%
ROE(3y)-126.09%
ROE(5y)-748.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.57
Quick Ratio 2.57
Altman-Z -8.05
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)80.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.27%
EPS Next Y62.04%
EPS Next 2Y35.06%
EPS Next 3Y29.28%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-21.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-8.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.78%
OCF growth 3YN/A
OCF growth 5YN/A